• About us
• Contact

Advertisement

Organisation › Details

Industrifonden, Malmö

Industrifonden provides capital, competence and networks to small and medium sized Swedish companies with international growth potential. It invests in companies requiring early-stage and expansion capital in the ICT, Life Science, Industrial Ventures and Cleantech sectors. It has total assets of SEK 3,000 million and holdings in about 90 companies. *

 

	Start	2012-01-05 existent
	Group	Sweden (govt)
	Industry	venture capital
	Industry 2	business development (state/region)
	Region	Malmö
	Country	Sweden
	Street	54 Norra Vallgatan
	City	21122 Malmö
		Address record changed: 2021-10-26
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Sweden (govt)

• [1] Oncopeptides AB. (3/8/23). "Press Release: Oncopeptides CSO Investigated for Violation of the Market Abuse Act"....
• [2] UK Government (Office for Life Sciences). (5/27/22). "Press Release: UK Commits to Life Sciences Cooperation with Sweden"....
• [3] Amniotics AB. (1/20/22). "Press Release: Amniotics Secures Funding of SEK 4,8 Million from Vinnova to Develop Stem Cell Therapies"....
• [4] EnginZyme AB. (2/11/21). "Press Release: EnginZyme Extends Series A to €11 Million to Advance Cell-Free Chemical Production Platform in Funding Round Led by Sweden’s Industrifonden". Stockholm....
• [5] Eir Ventures Partners AB. (7/10/20). "Press Release: New Nordic Life Science Venture Fund, Eir Ventures, Launched to Leverage the Untapped Potential of Health Care Innovation". Stockholm & Copenhagen....
• [6] Elypta AB. (1/23/20). "Press Release: Elypta Raises €6.1 Million in a Late Seed Round Led by Industrifonden"....
• [7] Gesynta Pharma AB. (4/4/19). "Press Release: Gesynta Pharma Secures 6 MEUR for Development Programs in Financing Round Led by Industrifonden". Solna....
• [8] Immunicum AB. (10/16/18). "Press Release: Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel - a New and Innovative Cancer Immunotherapy [Not for US, AU, CA, et al...
• [9] Immunicum AB. (10/16/18). "Press Release: Immunicum AB (publ) Clarifies Information Regarding Directed Issue [Not for US, AU, CA, et al.]"....
• [10] Immunicum AB. (10/16/18). "Press Release: Notice of Extraordinary General Meeting in Immunicum AB (publ)"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.